Search

Displaying results 5511 - 5520 of 8974 in total
  1. Drug

    MVA3000

    go.drugbank.com/drugs/DB05040
    Experimental

    MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or

  2. Drug

    Sagopilone

    go.drugbank.com/drugs/DB12391
    Investigational

    Epothilones are 16-member ring macrolides with antimicrotubule activity that share a similar mechanism of action to the taxanes but have demonstrated potent antiproliferative activity in several different … It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer.

  3. Drug

    Carmofur

    go.drugbank.com/drugs/DB09010
    ApprovedWithdrawn

    Carmofur has been known to induce leukoencephalopathy.

  4. Drug

    Tubercidin

    go.drugbank.com/drugs/DB03172
    Experimental

    An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids

  5. Drug

    Solabegron

    go.drugbank.com/drugs/DB06190
    Investigational

    Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.

    Categories: Drugs for Urinary Frequency and Incontinence
  6. Drug

    p-tert-Butylphenol-formaldehyde resin (low molecular weight)

    go.drugbank.com/drugs/DB14190
    Approved

    Sensitivity to p-tert-Butylphenol-formaldehyde resin may be identified with a clinical patch test.

  7. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474] … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  9. Drug

    Brofaromine

    go.drugbank.com/drugs/DB13876
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  10. Drug

    PGX-100

    go.drugbank.com/drugs/DB06114
    Investigational

    PGX-100 is an intravenous dosage form of modified heparin. … It is developed for treatment of exacerbation of obstructive pulmonary disease (COPD) and for the prevention and treatment of cardiac ischemia reperfusion injury (following acute myocardial infarction